UTHealth Therapeutic Antibody Core

Overview of Services

The successful clinical use of monoclonal antibodies is one of the most significant advances in cancer treatment today. Antibody-based therapies provide desirable attractive specificity, multiple mechanisms of action, and desirable safety profiles. Humanization, optimization for drug-like properties, and cloning antibody genes for expression in large quantities are labor-intensive processes requiring specialized equipment and expertise that challenge the translation of basic research to the discovery of drug candidates. The Therapeutic Antibody Core aims to provide state-wide support and service to advance lead antibodies from academic laboratories to the stage of preclinical development.

The facility offers specialized technical expertise, instrumentation, and automation in four major functional modules:

  • Lead identification;
  • Lead optimization;
  • Lead construction; and
  • Antibody production.

Our facility's instruments include:

  • QPix 420 Colony Picking System (Molecular Devices)
  • Multitron Pro Incubation Shaker (Infors)
  • BioRobot Universal System (Qiagen)
  • ReadyToProcess WAVE 25 Bioreactor (GE)
  • Octet RED96 system (forteBIO)


Consultation: prior to starting a project with the Core, you must schedule a consultation. Login to submit a consultation request or see below for contact info.


Zhiqiang An, PhD | Center Director

Ningyan Zhang, PhD | Co-Director

Location and hours of operation

Hours Location




The Brown Foundation Institute of Molecular Medicine for the

Prevention of Human Diseases | Texas Therapeutics Institute

1825 Pressler Street, SRB 530
Houston, TX77030

Scientific Advisory Board

Bruce D. Butler, Ph.D.

Vice President, Research & Technology, Office of Technology Management, UTHealth

Dean P. Edwards, Ph.D.

Associate Director, Research Infrastructure, Dan L. Duncan


Cancer Center. Executive Director, Advanced Technology Cores Baylor College of Medicine

Anil K. Sood, Ph.D.

Professor, Department of Gynecologic Oncology


The University of Texas MD Anderson Cancer Center

Guo-Liang Yu, Ph.D.

Executive Chairman, Crown Bioscience Inc.

E. Sally Ward, Ph.D.

Professor, Dept. of Molecular & Cellular Medicine and Dept. of Microbial Pathogenesis & Immunology


Texas A&M University      


Links and Resources

  1. Antibody Engineering & Expression Service Center
  2. An Z (2009) Therapeutic Monoclonal Antibodies: from Bench to Clinic (John Wiley and Sons, Hoboken, NJ)

  3. Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32(10):992-1000

  4. An Z (2010) Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1(4):319-330


Name Role Phone Email Location
Zhiqiang An, PhD
Hui Deng, PhD
Research Associate
SRB 501R
Xuejun Fan, PhD
Research Scientist
SRB 501R
Georgina To'a Salazar, PhD
Research Coordinator
SRB 530B
Robbie D. Schultz, PhD
Postdoctoral Research Fellow
SRB 501
Wei Xiong, PhD
Research Scientist
SRB 501R
Ningyan Zhang, PhD
Associate Professor
SRB 537D

Service list

Search available services: View: by category alphabetically
Individual Monoclonal Antibody Services (15)